Navigation Links
960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotech's Novel 5-FU Central Venous Catheter
Date:3/18/2008

occur when micro-organisms contaminate the catheter. Catheter related bloodstream infections are estimated to occur at an annual rate of 80,000 to 250,000 cases in the US, resulting in increased mortality, cost, and length of stay.(1-4) The attributable mortality of CRBSI is estimated at 11%.(5) In the U.S., the cost per catheter-related infection can range from $3,700 to $29,000.(6) In addition, the Centers for Disease Control and Prevention (CDC) has raised concerns about the overuse of traditional antibiotics and antiseptics, which can contribute to an increase in bacterial resistance.

About Angiotech's 5-FU CVC

Angiotech has demonstrated that 5-FU, a well-known and approved compound, has utility to prevent catheter-related infections as effectively as traditional antiseptics and antibiotics. In addition, since 5-FU has no clinical application as either a systemic antibiotic or a hospital antiseptic, there is a reduced risk to the hospital or the community at-large of creating a "super-bug" that may be resistant to useful classes of antibiotics and antispectics and may make infection control more complex. The alarming increase in microbial resistance is one of the CDC's top concerns.

The principle behind using 5-FU on a CVC is that the drug acts through multiple pathways to inhibit bacterial growth and metabolic functions of most microorganisms. Adding a very minute amount of 5-FU to the surface of a device makes that surface a very hostile environment for a microorganism, with unchanged tolerability for the patient. Our 5-FU technology can also effectively impair biofilm formation that may lead to colonization and infection. This reduction in colonization by bacteria may have a net effect of reducing biofilm burden on the implanted devices, making them less likely to serve as reservoirs for additional infection.

Note on Forward Looking Statements

Statements contained in this press release that are not based on historical fact,
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Sigma-Aldrich Corporation ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements ... expired on December 22, 2014, thereby completing the ... for the acquisition of the Company by Merck ... clearance satisfies another condition to closing the transaction, ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... 2014  ( www.competitivehealth.com ) — Competitive Health is ... review and advocacy service, has signed an agreement to ... discount health services marketplace. 63% of Americans ... they expected to pay. As part of an ongoing ... Savings is pleased to offer medical bill review and ...
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... (Nasdaq: SQNM ) is very pleased to ... 2011;342:c7401) of a groundbreaking international study led by our ... of Hong Kong. Building on early work from the ... of a large-scale clinical study that validates a noninvasive, ...
... MAR, Calif., Jan. 12, 2011 iDiverse today announced that ... Scientific Advisory Board. "We are extremely pleased to ... John Burr, president and CEO of iDiverse. "Dr. Miller has ... commercialization of novel bio-based technologies that have greatly improved the ...
... SeqWright Inc., a world-wide leader in custom genomic ... strides to position itself as the Next-Generation Sequencing ... can be attributed to the company,s ability to ... in key genomics technologies. Building on this success, ...
Cached Biology Technology:Professor Dennis Lo Trisomy 21 Clinical Validation Study Published in British Medical Journal 2Carl A. Miller, PhD, Joins iDiverse's Business and Scientific Advisory Board 2SeqWright Continues Expansion of Next-Generation Sequencing Capabilities 2
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has ... in the APAC Region 2015-2019"  report to their ... in this market is advances in technology. With ... upgrade biometric solutions to the latest standard that ...
(Date:12/11/2014)... N.C. , Dec. 10, 2014  That blood pressure ... quite a while. Hypertension – the medical term for high ... the early 1800s, and the inflatable cuff that,s used in ... doesn,t, however, mean there,s nothing new about hypertension, its triggers ... long-held beliefs about the condition and the best ways to ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... extinct in Europe 24,000 years ago, but until now the ... mitochondrial DNA sequences from 17 new fossil samples, and compared ... the decline of the cave bear started 50,000 years ago, ... change. "The decline in the genetic diversity of the ...
... University researcher has helped to locate and identify a gene ... terriers. This same gene may be responsible for a similar ... improved screening and diagnosis of the disease in dogs and ... both canines and humans. Dr. Natasha Olby, associate professor ...
... Spanish . A study led ... suggests that a water soluble extract of cinnamon, which ... with diabetes and heart disease. The ... Human Nutrition Research Center (BHNRC) operated by USDA,s ...
Cached Biology News:True causes for extinction of cave bear revealed 2Researchers find gene responsible for neurodegenerative disease in dogs, possibly in humans 2Researchers study cinnamon extracts 2